Previous close | 2.1000 |
Open | 2.1000 |
Bid | 1.5000 |
Ask | 2.0500 |
Strike | 17.50 |
Expiry date | 2024-06-21 |
Day's range | 2.1000 - 2.1000 |
Contract range | N/A |
Volume | |
Open interest | 88 |
Key Insights Innoviva's estimated fair value is US$19.59 based on 2 Stage Free Cash Flow to Equity Current share price...
BURLINGAME, Calif., June 03, 2024--Innoviva, Inc. (Nasdaq: INVA) ("Innoviva" or the "Company"), a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics ("IST"), and a portfolio of strategic investments in healthcare assets, today announced that Pavel Raifeld, Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami, FL
Strong Performance with Significant Growth in Net Product Revenue